Kamada Reiterates 2025 FY Revenue Guidance Of $178M-$182M
I'm PortAI, I can summarize articles.
Kamada Ltd announced the discontinuation of its Phase 3 inhaled AAT clinical trial due to unlikely statistically significant benefits. Despite this, the company reiterates its 2025 revenue guidance of $178M-$182M and projects double-digit growth in revenues and profitability in 2026. Kamada continues to supply Glassia internationally, including in the U.S. and Canada, through a license agreement with Takeda.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments